Supporting companies and start-up projects active in diagnostics, medtech pharmaceutical R&D.Track record (past and ongoing): -Medical devices for non-invasive, personalized therapy (arterial vascular diseases)-Preclinical contract research (cardiovascular disease models)-Therapeutic biologics in preclinical to clinical phase (oncology)-Non-targeted proteomics for early lung cancer detection in blood samples-Drug discovery contract research (infectious diseases, target identification/validation; repositioning)-Innovative biomarker technology for dermatological diagnostics-Targeted nanocarrier drug delivery for various indications/applications-Precision medicine multi-omics platform-First in class RNA-based immuno-oncology treatment (successfully sold to big pharma)-First in class DNA-based anti-inflammatory therapy (clinical stage, different chronic indications)-Novel virus-based anti-cancer therapy Advancing R&D processes and business development, activities including asset evaluation, market analysis, generating concepts/strategies, writing business and development plans/Target Product Profiles, regulatory documents and grant applications, QMS-implementation, identifying/auditing/managing CROs, planning/overseeing toxicology packages, operating DDs, developing concepts for patient stratification/next generation clinical trials, interacting with KOLs/experts, pharma/biotech stakeholders and regulatory bodies; Interim Management.

Discovery and development of novel anti-inflammatory small molecular drugs, e.g. pan-selectin antagonist Bimosiamose (Phase-II in COPD, Asthma, Psoriasis).